UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Restoration of the molecular clock is tumor suppressive in neuroblastoma

Nature communications, 2021-06, Vol.12 (1), p.4006-4006, Article 4006

2021

Volltextzugriff (PDF)

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

Nature communications, 2022-06, Vol.13 (1), p.3728-3728, Article 3728

2022

Volltextzugriff (PDF)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma

International journal of molecular sciences, 2021-06, Vol.22 (12), p.6565

2021

Volltextzugriff (PDF)

p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

Clinical cancer research, 2017-11, Vol.23 (21), p.6629-6639

2017

Volltextzugriff (PDF)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

Neoplasia (New York, N.Y.), 2021-06, Vol.23 (6), p.624-633

2021

Volltextzugriff (PDF)

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma

PloS one, 2013-11, Vol.8 (11), p.e79843-e79843

2013

Volltextzugriff (PDF)

G-CSF Receptor Positive Neuroblastoma Subpopulations Are Enriched in Chemotherapy-Resistant or Relapsed Tumors and Are Highly Tumorigenic

Cancer research (Chicago, Ill.), 2013-07, Vol.73 (13), p.4134-4146

2013

Volltextzugriff (PDF)

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

Molecular cancer therapeutics, 2006-09, Vol.5 (9), p.2358-2365

2006

Volltextzugriff (PDF)

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming

Advanced science, 2021-10, Vol.8 (19), p.e2005047-n/a

2021

Volltextzugriff (PDF)

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma

Angiogenesis (London), 2011-09, Vol.14 (3), p.255-266

2011

Volltextzugriff (PDF)

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo

Neoplasia (New York, N.Y.), 2009-08, Vol.11 (8), p.753-762

2009

Volltextzugriff (PDF)

Low birth weight for gestational age and subsequent male gonadal function

The Journal of pediatrics, 2002-09, Vol.141 (3), p.376-380

2002

Volltextzugriff (PDF)

Isolation and characterization of a novel GCSF responsive, highly tumorigenic subpopulation in neuroblastoma

Journal of the American College of Surgeons, 2010, Vol.211 (3), p.S69-S69

2010

Volltextzugriff (PDF)

Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF

Nucleic acids research, 2024-01, Vol.52 (1), p.4-21

2024

Volltextzugriff (PDF)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget, 2018-04, Vol.9 (29), p.20323-20338

2018

Volltextzugriff (PDF)

Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e22015-e22015

2022

Volltextzugriff (PDF)

Abstract A02: The epigenetic modifier CHAF1A opposes neuroblastoma differentiation via metabolic reprogramming

Molecular cancer research, 2015-10, Vol.13 (10_Supplement), p.A02-A02

2015

Volltextzugriff (PDF)

Abstract B44: The epigenetic modifier CHAF1A opposes neuroblastoma differentiation via metabolic reprogramming

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20_Supplement), p.B44-B44

2014

Volltextzugriff (PDF)

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Oncotarget, 2017-08, Vol.8 (34), p.57047-57057

2017

Volltextzugriff (PDF)

Abstract 1951: RORα activation opposes MYCN signaling and restores the circadian clock in neuroblastoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1951-1951

2017

Volltextzugriff (PDF)

Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (3), p.765-774

2014

Volltextzugriff (PDF)

Abstract A59: CHAF1A blocks neuroblastoma differentiation and promotes tumor growth via metabolic reprogramming

Molecular cancer research, 2016-01, Vol.14 (1_Supplement), p.A59-A59

2016

Volltextzugriff (PDF)

A Genome-Wide Search for Promoters That Respond to Increased MYCN Reveals Both New Oncogenic and Tumor Suppressor MicroRNAs Associated with Aggressive Neuroblastoma

Cancer research (Chicago, Ill.), 2011-06, Vol.71 (11), p.3841-3851

2011

Volltextzugriff (PDF)

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples

Scientific reports, 2016-11, Vol.6 (1), p.37876-37876, Article 37876

2016

Volltextzugriff (PDF)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget, 2018-07, Vol.9 (52), p.30024-30024

2018

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)
Buchkapitel
(1)

Sprache

Englisch
(36)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(17)
Humans
(16)
Animals
(12)
Neuroblastoma
(12)
Mice
(11)
Oncology
(11)
Neuroblastoma - Metabolism
(10)
Tumors
(9)
Cell Line, Tumor
(8)
Male
(8)
Neuroblastoma - Pathology
(8)
Female
(7)
Apoptosis
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Neuroblastoma - Genetics
(6)
Tumor Suppressor Protein P53 - Metabolism
(6)
Neuroblastoma - Drug Therapy
(5)
Science & Technology - Other Topics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Restoration of the molecular clock is tumor suppressive in neuroblastoma

MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma

p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma

G-CSF Receptor Positive Neuroblastoma Subpopulations Are Enriched in Chemotherapy-Resistant or Relapsed Tumors and Are Highly Tumorigenic

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo

Low birth weight for gestational age and subsequent male gonadal function

Isolation and characterization of a novel GCSF responsive, highly tumorigenic subpopulation in neuroblastoma

Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results

Abstract A02: The epigenetic modifier CHAF1A opposes neuroblastoma differentiation via metabolic reprogramming

Abstract B44: The epigenetic modifier CHAF1A opposes neuroblastoma differentiation via metabolic reprogramming

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Abstract 1951: RORα activation opposes MYCN signaling and restores the circadian clock in neuroblastoma

Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

Abstract A59: CHAF1A blocks neuroblastoma differentiation and promotes tumor growth via metabolic reprogramming

A Genome-Wide Search for Promoters That Respond to Increased MYCN Reveals Both New Oncogenic and Tumor Suppressor MicroRNAs Associated with Aggressive Neuroblastoma

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Suchergebnisse filtern